NEW YORK (GenomeWeb News) - Ariana Pharma, a Paris-based provider of drug discovery software tools, said today that it has raised €1.5 million ($2.3 million) through a private placement.
 
Vizille Capital Innovation, a subsidiary of the Crédit Mutuel - CIC bank, was the sole investor in the round and gained a minority stake in the firm. VCI joins Ariana's existing shareholders, the Pasteur Institute and company management.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.